JOP20180128A1 - صيغة دوائية صلبة قابلة للتشتت في الفم - Google Patents

صيغة دوائية صلبة قابلة للتشتت في الفم

Info

Publication number
JOP20180128A1
JOP20180128A1 JOP/2018/0128A JOP20180128A JOP20180128A1 JO P20180128 A1 JOP20180128 A1 JO P20180128A1 JO P20180128 A JOP20180128 A JO P20180128A JO P20180128 A1 JOP20180128 A1 JO P20180128A1
Authority
JO
Jordan
Prior art keywords
orally
pharmaceutical formulation
solid pharmaceutical
dispersible solid
ionic salt
Prior art date
Application number
JOP/2018/0128A
Other languages
English (en)
Inventor
Mohammad Ahmad Al-Remawi Mayyas
Tawfiq Al Akayleh Faisal
Original Assignee
Univ Of Petra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Petra filed Critical Univ Of Petra
Priority to JOP/2018/0128A priority Critical patent/JOP20180128A1/ar
Priority to PCT/JO2019/050003 priority patent/WO2020136691A1/en
Publication of JOP20180128A1 publication Critical patent/JOP20180128A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يقدم الكشف الحالي قرصًا صلبا قابل للتفتت في الفم وقد يشتمل القرص على واحد أو أكثر من المواد الفعالة وعلى الأقل ملح أيوني من أملاح الشيتوزان كسواغ ، حيث يشتمل ملح الشيتوزان الأيوني على أيونات متعددة التكافؤ.
JOP/2018/0128A 2018-12-24 2018-12-24 صيغة دوائية صلبة قابلة للتشتت في الفم JOP20180128A1 (ar)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JOP/2018/0128A JOP20180128A1 (ar) 2018-12-24 2018-12-24 صيغة دوائية صلبة قابلة للتشتت في الفم
PCT/JO2019/050003 WO2020136691A1 (en) 2018-12-24 2019-01-07 Orally-dispersible solid pharmaceutical formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JOP/2018/0128A JOP20180128A1 (ar) 2018-12-24 2018-12-24 صيغة دوائية صلبة قابلة للتشتت في الفم

Publications (1)

Publication Number Publication Date
JOP20180128A1 true JOP20180128A1 (ar) 2020-06-24

Family

ID=71129939

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2018/0128A JOP20180128A1 (ar) 2018-12-24 2018-12-24 صيغة دوائية صلبة قابلة للتشتت في الفم

Country Status (2)

Country Link
JO (1) JOP20180128A1 (ar)
WO (1) WO2020136691A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4159202A1 (en) * 2021-09-29 2023-04-05 Biomind Labs Inc Pharmaceutical formulation containing a psychedelic substance obtained by 3d printing by selective laser sintering (sls)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
ES2217797T3 (es) * 1998-08-14 2004-11-01 F. Hoffmann-La Roche Ag Vinileteres heterociclicos contra trastornos neurologicos.
GB0310919D0 (en) * 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
KR100815040B1 (ko) * 2005-01-31 2008-03-18 주식회사종근당 비스포스포네이트계 약물의 경구흡수 개선을 위한약제학적 조성물

Also Published As

Publication number Publication date
WO2020136691A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
WO2016149401A3 (en) Piperazine carbamates and methods of making and using same
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
MX2017016802A (es) Formulaciones farmaceuticas.
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
EP3894398A4 (en) 3,3-DIFLUORALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF
PH12017502322A1 (en) Therapeutic agent for fibrosis
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
EP3909597A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING AN OLIGOPEPTIDE AS ACTIVE INSTRUMENT
EP3488845A4 (en) FORMULATION HAVING IMPROVED PH-BASED MEDICATION RELEASE CHARACTERISTICS CONTAINING ESOMEPRAZOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
EP3539978A4 (en) NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION WITH IT AS THE ACTIVE INGREDIENT
MY183068A (en) Pharmaceutical formulation comprising antibody
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
JOP20180128A1 (ar) صيغة دوائية صلبة قابلة للتشتت في الفم
WO2018074880A3 (ko) 퀴놀린 4-온 유도체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 폐렴의 예방 또는 치료용 약학적 조성물
PH12018500579A1 (en) Fungal keratitis prophylactic or therapeutic agent
EP3599892C0 (en) CHEWABLE GEL PRODUCTS FOR PHARMACEUTICAL ACTIVE INGREDIENTS
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
EP3848039A4 (en) PHARMACEUTICAL COMPOSITION WITH A TSP1 PROTEIN INHIBITOR AS AN ACTIVE SUBSTANCE FOR THE PREVENTION OR TREATMENT OF FABRY DISEASE
WO2019059868A3 (en) PHARMACEUTICAL COMBINATIONS OF TENOFOVIR, EMTRICITABINE AND EFAVIRENZ
IN2014MU00043A (ar)